Terms ending in 2032
Every in-force patent on CSL Behring GmbH's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,352,016 | Factor XII Inhibitors for the Administration with Medical Procedures Comprising Contact with Artificial Surfaces In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 9,624,307 | Factor XII Inhibitors for the Treatment of Silent Brain Ischemia and Ischemia of Other Organs In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 9,987,328 | Factor XII Inhibitors for the Administration with Medical Procedures Comprising Contact with Artificial Surfaces In force · Medium confidence | CSL Behring GmbH | In force | Medium confidence | |
| US 9,856,325 | Nucleic Acids Encoding Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 9,856,326 | Methods of Administering Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 10,513,560 | Methods of Administering Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies In force · High confidence | CSL Ltd. | In force | High confidence | |
| US 12,558,422 | Immunoglobulin Preparation and Storage System for an Immunoglobulin Preparation In force · Low confidence | CSL Behring AG | In force | Low confidence | |
| US 9,452,203 | Use of C1-INHIBITOR for the Treatment of Secondary Edema of the Central Nervous System In force · High confidence | CSL Behring GmbH | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
7 of these are in force and held by CSL Behring GmbH.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.